180 related articles for article (PubMed ID: 32628300)
21. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
Burdelski C; Kleinhans S; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Marx A; Sauter G; Wittmer C; Huland H; Simon R; Schlomm T; Steurer S
Int J Cancer; 2016 Mar; 138(5):1199-206. PubMed ID: 26383228
[TBL] [Abstract][Full Text] [Related]
22. Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
Minner S; Lutz J; Hube-Magg C; Kluth M; Simon R; Höflmayer D; Burandt E; Tsourlakis MC; Sauter G; Büscheck F; Wilczak W; Steurer S; Schlomm T; Huland H; Graefen M; Haese A; Heinzer H; Jacobsen F; Hinsch A; Poos A; Oswald M; Rippe K; König R; Schroeder C
Prostate; 2019 Feb; 79(3):302-311. PubMed ID: 30430607
[TBL] [Abstract][Full Text] [Related]
23. Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients.
Büscheck F; Sulimankhil M; Melling N; Höflmayer D; Hube-Magg C; Simon R; Göbel C; Hinsch A; Weidemann S; Izbicki JR; Jacobsen F; Mandelkow T; Blessin NC; Möller-Koop C; Lutz F; Viehweger F; Möller K; Sauter G; Lennartz M; Burandt E; Lebok P; Minner S; Bonk S; Huland H; Graefen M; Schlomm T; Fraune C
Cancer Med; 2020 Feb; 9(4):1409-1418. PubMed ID: 31893572
[TBL] [Abstract][Full Text] [Related]
24. Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer.
Kind S; Büscheck F; Höflmayer D; Hube-Magg C; Kluth M; Tsourlakis MC; Steurer S; Clauditz TS; Luebke AM; Burandt E; Wilczak W; Hinsch A; Dum D; Weidemann S; Fraune C; Beyer B; Steuber T; Huland H; Graefen M; Fisch M; Simon R; Sauter G; Schlomm T; Minner S; Eichenauer T
World J Urol; 2020 Sep; 38(9):2185-2196. PubMed ID: 31745645
[TBL] [Abstract][Full Text] [Related]
25. The Significance of ERG and Androgen Receptor Expression in Adenocarcinoma Prostate.
Husain I; Sagar P; Shukla S; Babu S; Singhai A; Sankhwar SN; Husain N
Kathmandu Univ Med J (KUMJ); 2018 Oct.-Dec.; 16(64):277-280. PubMed ID: 31729338
[TBL] [Abstract][Full Text] [Related]
26. Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer.
Jacobsen F; Taskin B; Melling N; Sauer C; Wittmer C; Hube-Magg C; Kluth M; Simon R; Pehrke D; Beyer B; Steuber T; Thederan I; Sauter G; Schlomm T; Wilczak W; Möller K; Weidemann SA; Burdak-Rothkamm S
BMC Cancer; 2017 Jul; 17(1):504. PubMed ID: 28747165
[TBL] [Abstract][Full Text] [Related]
27. PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer.
Heinrich MC; Göbel C; Kluth M; Bernreuther C; Sauer C; Schroeder C; Möller-Koop C; Hube-Magg C; Lebok P; Burandt E; Sauter G; Simon R; Huland H; Graefen M; Heinzer H; Schlomm T; Heumann A
BMC Cancer; 2018 May; 18(1):612. PubMed ID: 29855276
[TBL] [Abstract][Full Text] [Related]
28. Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer.
Jacobsen F; Kraft J; Schroeder C; Hube-Magg C; Kluth M; Lang DS; Simon R; Sauter G; Izbicki JR; Clauditz TS; Luebke AM; Hinsch A; Wilczak W; Wittmer C; Büscheck F; Höflmayer D; Minner S; Tsourlakis MC; Huland H; Graefen M; Budäus L; Thederan I; Salomon G; Schlomm T; Melling N
Neoplasia; 2017 Sep; 19(9):707-715. PubMed ID: 28830008
[TBL] [Abstract][Full Text] [Related]
29. p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.
Burdelski C; Dieckmann T; Heumann A; Hube-Magg C; Kluth M; Beyer B; Steuber T; Pompe R; Graefen M; Simon R; Minner S; Tsourlakis MC; Koop C; Izbicki J; Sauter G; Krech T; Schlomm T; Wilczak W; Lebok P
Tumour Biol; 2016 Sep; 37(9):12655-12663. PubMed ID: 27444279
[TBL] [Abstract][Full Text] [Related]
30. Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer.
Höflmayer D; Steinhoff A; Hube-Magg C; Kluth M; Simon R; Burandt E; Tsourlakis MC; Minner S; Sauter G; Büscheck F; Wilczak W; Steurer S; Huland H; Graefen M; Haese A; Heinzer H; Schlomm T; Jacobsen F; Hinsch A; Poos AM; Oswald M; Rippe K; König R; Schroeder C
Mol Oncol; 2020 Jan; 14(1):129-138. PubMed ID: 31736271
[TBL] [Abstract][Full Text] [Related]
31. Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion.
Fraune C; Harms L; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Möller K; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Sauter G; Weidemann S; Lebok P; Dum D; Kind S; Minner S; Izbicki JR; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Schroeder C
Mol Med; 2020 Mar; 26(1):24. PubMed ID: 32143573
[TBL] [Abstract][Full Text] [Related]
32. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.
Stumm L; Burkhardt L; Steurer S; Simon R; Adam M; Becker A; Sauter G; Minner S; Schlomm T; Sirma H; Michl U
J Clin Pathol; 2013 Jul; 66(7):563-8. PubMed ID: 23559350
[TBL] [Abstract][Full Text] [Related]
33. The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer.
Büscheck F; Zub M; Heumann A; Hube-Magg C; Simon R; Lang DS; Höflmayer D; Neubauer E; Jacobsen F; Hinsch A; Luebke AM; Tsourlakis MC; Sauter G; Huland H; Graefen M; Haese A; Heinzer H; Schlomm T; Clauditz TS; Burandt E; Wilczak W; Steurer S; Minner S
Tumour Biol; 2019 Jul; 41(7):1010428318824815. PubMed ID: 31296150
[TBL] [Abstract][Full Text] [Related]
34. Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels.
Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Lorente JA; Fumado L; Serrano L; Serrano S; Lloreta J; Hernández S
Prostate; 2015 Aug; 75(11):1216-26. PubMed ID: 25939480
[TBL] [Abstract][Full Text] [Related]
35. KPNA2/ERG Coexpression is Associated With Early Recurrence in Advanced Prostate Cancers.
D'Antonio A; Caputo A; Fraggetta F; Pepe P; Insabato L; Barra E; Barresi V; Altieri V; Greco U; Savastano R; Zeppa P
Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):62-66. PubMed ID: 31809312
[TBL] [Abstract][Full Text] [Related]
36. High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer.
Melling N; Harutyunyan L; Hube-Magg C; Kluth M; Simon R; Lebok P; Minner S; Tsourlakis MC; Koop C; Graefen M; Adam M; Haese A; Wittmer C; Steurer S; Izbicki J; Sauter G; Wilczak W; Schlomm T; Krech T
PLoS One; 2015; 10(7):e0134614. PubMed ID: 26230842
[TBL] [Abstract][Full Text] [Related]
37. Deletion of 8p is an independent prognostic parameter in prostate cancer.
Kluth M; Amschler NN; Galal R; Möller-Koop C; Barrow P; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Steurer S; Krech T; Büscheck F; Clauditz TS; Beyer B; Wilczak W; Graefen M; Huland H; Minner S; Schlomm T; Sauter G; Simon R
Oncotarget; 2017 Jan; 8(1):379-392. PubMed ID: 27880722
[TBL] [Abstract][Full Text] [Related]
38. Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer.
Schroeder C; Grell J; Hube-Magg C; Kluth M; Lang D; Simon R; Höflmayer D; Minner S; Burandt E; Clauditz TS; Büscheck F; Jacobsen F; Huland H; Graefen M; Schlomm T; Sauter G; Steurer S
BMC Cancer; 2019 Mar; 19(1):193. PubMed ID: 30823906
[TBL] [Abstract][Full Text] [Related]
39. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
40. Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.
Burdelski C; Borcherding L; Kluth M; Hube-Magg C; Melling N; Simon R; Möller-Koop C; Weigand P; Minner S; Haese A; Michl HU; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Lebok P; Steurer S; Izbicki JR; Sauter G; Krech T; Büscheck F; Clauditz T; Schlomm T; Wilczak W
Oncotarget; 2017 May; 8(19):31494-31508. PubMed ID: 28415558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
